- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | CytomX surges on positive data for 'masked' ADC in colorectal cancer | ||
| Mo | Structure's GLP-1 pill shows 'best-in-class' potential in obesity trial | ||
| Mo | Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy | ||
| Fr | With FDA go ahead, a China biotech notches a first in cell therapy testing | ||
| Fr | GSK's RSV vaccine wins broader FDA clearance | ||
| Fr | Evotec, Vistagen lay off staff; Immutep shares collapse on study failure | ||
| Fr | New FDA guidance could elevate pharma's biosimilar market | ||
| Do | Lilly warns GLP-1 knockoffs may be 'dangerous,' escalating war with compounders | ||
| Do | FDA to unify agency's 'fragmented' safety surveillance system | ||
| Mi | Biogen builds case for Spinraza successor with fresh data | ||
| Mi | FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism | ||
| Mi | Lilly unveils $3 billion production expansion in China | ||
| Mi | Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial | ||
| Mi | With $100M, Vima pursues an oral drug for movement disorders | ||
| 10.03. | BioNTech founders to step down and helm new mRNA startup | ||
| 10.03. | Xenon hits a 'home run' in epilepsy; FDA restarts review of Duchenne cell therapy | ||
| 09.03. | Vertex kidney disease drug hits mark in late-stage study | ||
| 09.03. | Bristol Myers claims success in study of another next-gen blood cancer drug | ||
| 09.03. | Roche's prized breast cancer pill fails closely watched study | ||
| 09.03. | UniQure leads genetic medicine biotech rally after news of Prasad's exit | ||
| 09.03. | Ipsen to withdraw cancer drug acquired in buyout due to safety concerns | ||
| 09.03. | Novo, Hims reach deal to sell GLP-1 drugs together | ||
| 09.03. | Navigating the PPQ process: Proven strategies to safeguard quality for cell and gene therapies | ||
| 09.03. | Rethinking the box: Why circular cold chain packaging is becoming a cost strategy in healthcare | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.